3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
12
Phase 3
4
Phase 1/2
4
Phase NA
3
Phase 1
3
Phase EARLY_PHASE1
1
Phase 2/3
1
Status
Recruiting
3
Completed
1
Sponsor Class
OTHER
2
INDUSTRY
2
Study Type
Interventional
4
Sponsor
Cancer Type
Gynecologic
2
Breast
2
Other solid neoplasm
1
Head & Neck
1
Genitourinary
1
Conditions
Endometrial Neoplasms
2
Breast Neoplasms
2
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Prostate Cancer Recurrent
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
Breast Diseases
1
Interventions
pembrolizumab
79
Cyclophosphamide
55
Specimen Handling
54
Carboplatin
50
fludarabine
44
Nivolumab
42
Magnetic Resonance Spectroscopy
42
Biopsy
38
Gemcitabine
37
Bevacizumab
34
Dexamethasone
31
venetoclax
27
Paclitaxel
26
Injections
25
Docetaxel
25
atezolizumab
24
Pemetrexed
24
Cisplatin
24
Ipilimumab
23
Capecitabine
21
Temozolomide
19
Fulvestrant
19
abemaciclib
18
Rituximab
18
Oxaliplatin
18
Lenalidomide
18
Cetuximab
18
Azacitidine
18
Vincristine
15
Fluorouracil
15
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
4 trials
Recent
Start date
Enrollment
Phase 1/2
×
Metformin
×
90 days
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled
NCT02755844
2026-05-27
ENDOLA
Hospices Civils de Lyon
Phase 1/2
Completed
35 enrolled
NCT05036226
2026-05-13
COAST
Medical University of South Carolina
Phase 1/2
Recruiting
76 enrolled
NCT03424005
2026-03-16
Morpheus-panBC
Hoffmann-La Roche
Phase 1/2
Recruiting
792 enrolled